Drug Repackagers Could Be Liable For Medicaid Rebates Due To Pending FDA Rule
Executive Summary
BOSTON - Drug wholesalers that repackage drugs may face responsibilities for paying Medicaid drug rebates, should an FDA rule on relabeling be made final
You may also be interested in...
Orphan Drug Czar Will Push Legislators For More Grant Funding In 2008
For the past 15 years, funding for the grants program at FDA's Office of Orphan Products Development has remained stagnant at $14 million
Shire Shuffles Corporate Leadership: CFO Russell Rises To CEO
Chairman Cavanaugh retires, to be replaced in June by former chief exec Emmens.
GSK And Takeda Challenge Latest Data Linking TZDs To Cardiovascular Events
Retrospective analysis by Canadian institute points to increased risk of congestive heart failure; acute MI appears limited to Avandia.